ALISON L. HANNAH, M.D.

Corporate Board Profile

Tech Score: 0/100

RIGEL PHARMACEUTICALS INC

Filing Date	Source Excerpt
2022-04-05	Alison L. Hannah, M.D., age 61, joined us as a director in May 2021. Dr. Hannah brings over three decades of pharmaceutical industry experience to Rigel, including a deep knowledge of clinical development strategy in hematology and oncology with a focus on molecularly targeted therapies. Dr. Hannah currently serves as chief medical officer for CytomX Therapeutics, Inc. ... Dr. Hannah was selected to serve as a member of the Board in part due to her extensive expertise in clinical development strategy and regulatory filings, broad clinical operational experience, which is particularly relevant to our business as we are a company focused on hematologic disorders, cancer and rare immune diseases.
2023-04-14	Alison L. Hannah, M.D., age 62, joined us as a director in May 2021. Dr. Hannah has served as a consultant to the pharmaceutical and biotechnology industry since 2000, directing the development of investigational cancer therapies. ... Dr. Hannah serves on the board of directors for Neogenomics, a cancer diagnostic firm. ... Dr. Hannah was selected to serve as a member of the Board in part due to her extensive expertise in clinical development strategy and regulatory filings, broad clinical operational experience, which is particularly relevant to our business as we are a company focused on hematologic disorders, cancer and rare immune diseases. ... The following directors are currently members of the Corporate Governance, Health Care Compliance Oversight and Nominating Committee: Dr. Hannah ... The following directors are currently members of the Scientific and Clinical Trial Advisory Committee: Dr. Hannah ... The following table shows the compensation of all non-employee directors of the Company for the fiscal year ended December 31, 2022: Alison L. Hannah, M.D. Fees Earned or Paid in Cash ($) 66,181 Stock Awards ($) 50,250 Option Awards ($) 40,926 Total ($) 157,357.

Filing Date

Source Excerpt

2022-04-05

Alison L. Hannah, M.D., age 61, joined us as a director in May 2021. Dr. Hannah brings over three decades of pharmaceutical industry experience to Rigel, including a deep knowledge of clinical development strategy in hematology and oncology with a focus on molecularly targeted therapies. Dr. Hannah currently serves as chief medical officer for CytomX Therapeutics, Inc. ... Dr. Hannah was selected to serve as a member of the Board in part due to her extensive expertise in clinical development strategy and regulatory filings, broad clinical operational experience, which is particularly relevant to our business as we are a company focused on hematologic disorders, cancer and rare immune diseases.

2023-04-14

Alison L. Hannah, M.D., age 62, joined us as a director in May 2021. Dr. Hannah has served as a consultant to the pharmaceutical and biotechnology industry since 2000, directing the development of investigational cancer therapies. ... Dr. Hannah serves on the board of directors for Neogenomics, a cancer diagnostic firm. ... Dr. Hannah was selected to serve as a member of the Board in part due to her extensive expertise in clinical development strategy and regulatory filings, broad clinical operational experience, which is particularly relevant to our business as we are a company focused on hematologic disorders, cancer and rare immune diseases. ... The following directors are currently members of the Corporate Governance, Health Care Compliance Oversight and Nominating Committee: Dr. Hannah ... The following directors are currently members of the Scientific and Clinical Trial Advisory Committee: Dr. Hannah ... The following table shows the compensation of all non-employee directors of the Company for the fiscal year ended December 31, 2022: Alison L. Hannah, M.D. Fees Earned or Paid in Cash ($) 66,181 Stock Awards ($) 50,250 Option Awards ($) 40,926 Total ($) 157,357.

Data sourced from SEC filings. Last updated: 2026-03-05